JP2013523710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523710A5 JP2013523710A5 JP2013501951A JP2013501951A JP2013523710A5 JP 2013523710 A5 JP2013523710 A5 JP 2013523710A5 JP 2013501951 A JP2013501951 A JP 2013501951A JP 2013501951 A JP2013501951 A JP 2013501951A JP 2013523710 A5 JP2013523710 A5 JP 2013523710A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- pyrazol
- ureido
- pyridin
- dichlorophenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 n- propyl Chemical group 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 6
- 239000004202 carbamide Substances 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- VLMPAMYESBASPG-UHFFFAOYSA-N 1-[2,3-dichloro-4-[2-(methylcarbamoylamino)pyridin-4-yl]oxyphenyl]-3-[5-(1-methylcyclohexyl)-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C3(C)CCCCC3)C=3C=CC(C)=CC=3)=CC=2)Cl)=C1 VLMPAMYESBASPG-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000000155 isotopic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- OIAZQNDOMLQBTC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(2-hydroxyethylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)NCCO)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 OIAZQNDOMLQBTC-UHFFFAOYSA-N 0.000 claims 1
- PRRTTXQJXYIWIX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(2-methoxyethylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NCCOC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 PRRTTXQJXYIWIX-UHFFFAOYSA-N 0.000 claims 1
- YBGBLFUNGGROBC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(2-morpholin-4-ylethylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)NCCN4CCOCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 YBGBLFUNGGROBC-UHFFFAOYSA-N 0.000 claims 1
- NHMKKTQJKOFNIJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(3-imidazol-1-ylpropylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)NCCCN4C=NC=C4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 NHMKKTQJKOFNIJ-UHFFFAOYSA-N 0.000 claims 1
- QPXKCTOLMAYCEZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(cyclopropylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)NC4CC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 QPXKCTOLMAYCEZ-UHFFFAOYSA-N 0.000 claims 1
- AJHNLMKJRISUFA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(ethylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NCC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 AJHNLMKJRISUFA-UHFFFAOYSA-N 0.000 claims 1
- MMMMQLITLMJIGS-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound CNC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=N1 MMMMQLITLMJIGS-UHFFFAOYSA-N 0.000 claims 1
- UXNCEUAZOJVHSD-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-[2-(dimethylamino)ethylcarbamoylamino]pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)NCCN(C)C)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 UXNCEUAZOJVHSD-UHFFFAOYSA-N 0.000 claims 1
- AHTMBXGKCASMLK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[6-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=N1 AHTMBXGKCASMLK-UHFFFAOYSA-N 0.000 claims 1
- SMTVTISHQTTWIJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[[2-(methylcarbamoylamino)pyridin-4-yl]methoxy]phenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(COC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 SMTVTISHQTTWIJ-UHFFFAOYSA-N 0.000 claims 1
- USMGBMVEIONWEF-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2-chloro-3-cyano-4-[2-(cyclopropylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(C#N)C(OC=3C=C(NC(=O)NC4CC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 USMGBMVEIONWEF-UHFFFAOYSA-N 0.000 claims 1
- JWNUKWIUEVMBCP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[5-[2-(methylcarbamoylamino)pyridin-4-yl]oxyquinolin-8-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C3=CC=CN=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)=C1 JWNUKWIUEVMBCP-UHFFFAOYSA-N 0.000 claims 1
- MKRDTPRFOOZKLJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[8-[2-(methylcarbamoylamino)pyridin-4-yl]oxyquinolin-5-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C3=NC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)=C1 MKRDTPRFOOZKLJ-UHFFFAOYSA-N 0.000 claims 1
- DVERJTHQZPGXQN-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(methylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=C1 DVERJTHQZPGXQN-UHFFFAOYSA-N 0.000 claims 1
- NKFGXRJEGVLHPA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound CNC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=N1 NKFGXRJEGVLHPA-UHFFFAOYSA-N 0.000 claims 1
- DUZLWGRPUKUKRC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[6-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=N1 DUZLWGRPUKUKRC-UHFFFAOYSA-N 0.000 claims 1
- PARGWSHOODCFOD-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[6-[2-(dimethylamino)ethylcarbamoylamino]pyrimidin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NCCN(C)C)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=N1 PARGWSHOODCFOD-UHFFFAOYSA-N 0.000 claims 1
- OVBTUBSHWNGHEB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[[2-(methylcarbamoylamino)pyridin-4-yl]methoxy]phenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(COC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=C1 OVBTUBSHWNGHEB-UHFFFAOYSA-N 0.000 claims 1
- SRVVSDBSTURJMJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-[2-(methylcarbamoylamino)pyridin-4-yl]oxyquinolin-8-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C3=CC=CN=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 SRVVSDBSTURJMJ-UHFFFAOYSA-N 0.000 claims 1
- USWDEAODPRGOFK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[8-[[2-(methylcarbamoylamino)pyridin-4-yl]methoxy]quinolin-5-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(COC=2C3=NC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 USWDEAODPRGOFK-UHFFFAOYSA-N 0.000 claims 1
- CSEFAOSXZQCHNC-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(2-morpholin-4-ylethylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C=1C=C(CO)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(C=1)=CC=NC=1NC(=O)NCCN1CCOCC1 CSEFAOSXZQCHNC-UHFFFAOYSA-N 0.000 claims 1
- BSMRUQMZPUPKCC-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(cyclopropylcarbamoylamino)pyridin-4-yl]oxyphenyl]urea Chemical compound C=1C=C(CO)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(C=1)=CC=NC=1NC(=O)NC1CC1 BSMRUQMZPUPKCC-UHFFFAOYSA-N 0.000 claims 1
- VVBJANIWLGGZJB-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[2,3-dichloro-4-[2-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound CNC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=N1 VVBJANIWLGGZJB-UHFFFAOYSA-N 0.000 claims 1
- NFEGIIQSUSSDLM-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[2,3-dichloro-4-[2-[2-(dimethylamino)ethylcarbamoylamino]pyridin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NCCN(C)C)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=C1 NFEGIIQSUSSDLM-UHFFFAOYSA-N 0.000 claims 1
- DKVWSSQEESVPSA-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[2,3-dichloro-4-[6-(methylcarbamoylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=N1 DKVWSSQEESVPSA-UHFFFAOYSA-N 0.000 claims 1
- YZZUDFVTYXDQEJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[5-[2-(methylcarbamoylamino)pyridin-4-yl]oxyquinolin-8-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C3=CC=CN=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)=C1 YZZUDFVTYXDQEJ-UHFFFAOYSA-N 0.000 claims 1
- KEUPSXIYJHLGEW-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[8-[2-(methylcarbamoylamino)pyridin-4-yl]oxyquinolin-5-yl]urea Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C3=NC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)=C1 KEUPSXIYJHLGEW-UHFFFAOYSA-N 0.000 claims 1
- ZLAAPNRAYFZHNK-UHFFFAOYSA-N 1-methyl-3-pyridin-2-ylurea Chemical compound CNC(=O)NC1=CC=CC=N1 ZLAAPNRAYFZHNK-UHFFFAOYSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- XIPWBCORXDYDEH-UHFFFAOYSA-N 3-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-1,1-dimethylurea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N(C)C)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 XIPWBCORXDYDEH-UHFFFAOYSA-N 0.000 claims 1
- MDRDQUUSTQLWDS-UHFFFAOYSA-N 4-[3-tert-butyl-5-[[2,3-dichloro-4-[2-(methylcarbamoylamino)pyridin-4-yl]oxyphenyl]carbamoylamino]pyrazol-1-yl]benzoic acid Chemical compound C1=NC(NC(=O)NC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(=CC=3)C(O)=O)=CC=2)Cl)=C1 MDRDQUUSTQLWDS-UHFFFAOYSA-N 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- WBTMEQBEZBHVLX-UHFFFAOYSA-N n-[4-[2,3-dichloro-4-[[5-(1-methylcyclohexyl)-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]phenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C2(C)CCCCC2)=N1 WBTMEQBEZBHVLX-UHFFFAOYSA-N 0.000 claims 1
- PTCQZSYEIRXAIN-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-hydroxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(O)=CC=3)=CC=2)Cl)=C1 PTCQZSYEIRXAIN-UHFFFAOYSA-N 0.000 claims 1
- CZDHOGUMUFVZCC-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-hydroxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C=1C=C(O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(C=1)=CC=NC=1NC(=O)N1CCCC1 CZDHOGUMUFVZCC-UHFFFAOYSA-N 0.000 claims 1
- QPMSRTROJIEXKZ-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2,2-dimethylpyrrolidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4C(CCC4)(C)C)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 QPMSRTROJIEXKZ-UHFFFAOYSA-N 0.000 claims 1
- URHWXOQMBIQOBQ-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 URHWXOQMBIQOBQ-UHFFFAOYSA-N 0.000 claims 1
- VEWLUNVBOUIWGE-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-morpholin-4-ylacetamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)CN4CCOCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 VEWLUNVBOUIWGE-UHFFFAOYSA-N 0.000 claims 1
- TZMPHXDDWVQDHH-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4CC(O)CC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 TZMPHXDDWVQDHH-UHFFFAOYSA-N 0.000 claims 1
- KIJXCHMCGNRFQQ-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 KIJXCHMCGNRFQQ-UHFFFAOYSA-N 0.000 claims 1
- SIQMUTQLUKGUQN-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-2-yl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=N1 SIQMUTQLUKGUQN-UHFFFAOYSA-N 0.000 claims 1
- CVJOJNAYZTXXLX-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-3-chloro-2-cyanophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(C#N)C(OC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 CVJOJNAYZTXXLX-UHFFFAOYSA-N 0.000 claims 1
- JSIFEAJIXNCCLD-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=C1 JSIFEAJIXNCCLD-UHFFFAOYSA-N 0.000 claims 1
- XQLDEOFPWWTZDI-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 XQLDEOFPWWTZDI-UHFFFAOYSA-N 0.000 claims 1
- OXYANFFCSSZNGD-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-2-yl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=N1 OXYANFFCSSZNGD-UHFFFAOYSA-N 0.000 claims 1
- IVXZQBKYEVXDCC-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-difluorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)F)=C1 IVXZQBKYEVXDCC-UHFFFAOYSA-N 0.000 claims 1
- VBDADDXQNNCWKR-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,5-dichlorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=C(Cl)C=2)Cl)=C1 VBDADDXQNNCWKR-UHFFFAOYSA-N 0.000 claims 1
- IJDGLJNPNVTWDM-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2-(trifluoromethyl)phenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)C(F)(F)F)=C1 IJDGLJNPNVTWDM-UHFFFAOYSA-N 0.000 claims 1
- XCQLGETYJSGQCY-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2-methylsulfonylphenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)S(C)(=O)=O)=C1 XCQLGETYJSGQCY-UHFFFAOYSA-N 0.000 claims 1
- RKZSLFYAENDMNY-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-3-(trifluoromethyl)phenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C=C(C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)C(F)(F)F)=C1 RKZSLFYAENDMNY-UHFFFAOYSA-N 0.000 claims 1
- FDHGBSRBIGBHQC-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-3-chloro-2-(trifluoromethyl)phenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)C(F)(F)F)=C1 FDHGBSRBIGBHQC-UHFFFAOYSA-N 0.000 claims 1
- WYANJWLOZNEICQ-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-3-chloro-2-cyanophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)C#N)=C1 WYANJWLOZNEICQ-UHFFFAOYSA-N 0.000 claims 1
- UXISBAJFIIIQHI-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-3-chloro-2-fluorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)F)=C1 UXISBAJFIIIQHI-UHFFFAOYSA-N 0.000 claims 1
- CKJSDKNLBGHJCR-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-3-methylsulfonylphenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C=C(C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)S(C)(=O)=O)=C1 CKJSDKNLBGHJCR-UHFFFAOYSA-N 0.000 claims 1
- ZSBGLUVHHWVFNF-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-5-chloro-2-fluorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=C(Cl)C=2)F)=C1 ZSBGLUVHHWVFNF-UHFFFAOYSA-N 0.000 claims 1
- TXJNFPHFHSHWMX-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylsulfanylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 TXJNFPHFHSHWMX-UHFFFAOYSA-N 0.000 claims 1
- FGAOSVCLISNSHF-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=C1 FGAOSVCLISNSHF-UHFFFAOYSA-N 0.000 claims 1
- CNNQFIKMULLKJN-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(CO)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(C=1)=CC=NC=1NC(=O)CN1CCOCC1 CNNQFIKMULLKJN-UHFFFAOYSA-N 0.000 claims 1
- DLCRSFNRWFGILM-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C=1C=C(CO)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(C=1)=CC=NC=1NC(=O)N1CCCC1 DLCRSFNRWFGILM-UHFFFAOYSA-N 0.000 claims 1
- XLRYXRRLGRJESM-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-2-yl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=NC=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=N1 XLRYXRRLGRJESM-UHFFFAOYSA-N 0.000 claims 1
- XJDYOCRRPVKPQO-UHFFFAOYSA-N n-[4-[6-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-difluorophenoxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(F)C=CC=2NC(=O)NC=2N(N=C(C=2)C(C)(C)C)C=2C=CC(C)=CC=2)F)=C1 XJDYOCRRPVKPQO-UHFFFAOYSA-N 0.000 claims 1
- YKLTVWLJVJBTQF-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]methyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(COC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 YKLTVWLJVJBTQF-UHFFFAOYSA-N 0.000 claims 1
- CVKWJEKIFPWRIE-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]methyl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OCC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 CVKWJEKIFPWRIE-UHFFFAOYSA-N 0.000 claims 1
- BRVXEYILXFKRHV-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenyl]sulfanylmethyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(CSC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=C1 BRVXEYILXFKRHV-UHFFFAOYSA-N 0.000 claims 1
- HCRJGKWVFQOYRB-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]methyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(COC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=C1 HCRJGKWVFQOYRB-UHFFFAOYSA-N 0.000 claims 1
- JZUBZTZKPCGNRK-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]methyl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OCC=3C=C(NC(=O)N4CCCC4)N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 JZUBZTZKPCGNRK-UHFFFAOYSA-N 0.000 claims 1
- WMWXYOQRAMOAJE-UHFFFAOYSA-N n-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C=3CCCCC=3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 WMWXYOQRAMOAJE-UHFFFAOYSA-N 0.000 claims 1
- QZEGYHJHDSAXMB-UHFFFAOYSA-N n-[4-[[5-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]quinolin-8-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(COC=2C3=NC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)=C1 QZEGYHJHDSAXMB-UHFFFAOYSA-N 0.000 claims 1
- MDLVXCAENWAJAD-UHFFFAOYSA-N n-[4-[[5-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]quinolin-8-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(COC=2C3=NC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 MDLVXCAENWAJAD-UHFFFAOYSA-N 0.000 claims 1
- IUQCOTNIPARRBG-UHFFFAOYSA-N n-[4-[[7-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-1h-indazol-4-yl]oxy]pyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C=3C=NNC=3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 IUQCOTNIPARRBG-UHFFFAOYSA-N 0.000 claims 1
- CJDHCDKZYJEROE-UHFFFAOYSA-N n-[6-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-4-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(OC)=CC=3)=CC=2)Cl)=N1 CJDHCDKZYJEROE-UHFFFAOYSA-N 0.000 claims 1
- ZJGQZIMHLMTNEV-UHFFFAOYSA-N n-[6-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-4-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)Cl)=N1 ZJGQZIMHLMTNEV-UHFFFAOYSA-N 0.000 claims 1
- HLSACCNVCQFECH-UHFFFAOYSA-N n-[6-[4-[[5-tert-butyl-2-[3-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-4-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C(CO)C=CC=3)=CC=2)Cl)=N1 HLSACCNVCQFECH-UHFFFAOYSA-N 0.000 claims 1
- NNNKDWVPDQOPGX-UHFFFAOYSA-N n-[6-[4-[[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-2,3-dichlorophenoxy]pyrimidin-4-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C(=C(Cl)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(CO)=CC=3)=CC=2)Cl)=N1 NNNKDWVPDQOPGX-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- MQDVUDAZJMZQMF-UHFFFAOYSA-N pyridin-2-ylurea Chemical compound NC(=O)NC1=CC=CC=N1 MQDVUDAZJMZQMF-UHFFFAOYSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1005589.5 | 2010-04-01 | ||
| GBGB1005589.5A GB201005589D0 (en) | 2010-04-01 | 2010-04-01 | Novel compounds |
| PCT/GB2011/050668 WO2011121366A1 (en) | 2010-04-01 | 2011-04-01 | Pyrazole p38 map kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523710A JP2013523710A (ja) | 2013-06-17 |
| JP2013523710A5 true JP2013523710A5 (enExample) | 2014-05-08 |
| JP5902668B2 JP5902668B2 (ja) | 2016-04-13 |
Family
ID=42228808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501951A Active JP5902668B2 (ja) | 2010-04-01 | 2011-04-01 | ピラゾール系ｐ３８ＭＡＰキナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20130029990A1 (enExample) |
| EP (1) | EP2556065B1 (enExample) |
| JP (1) | JP5902668B2 (enExample) |
| ES (1) | ES2532764T3 (enExample) |
| GB (1) | GB201005589D0 (enExample) |
| WO (1) | WO2011121366A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| DK2531502T3 (da) | 2010-02-01 | 2014-05-19 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
| GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
| SG11201402985VA (en) * | 2011-12-09 | 2014-08-28 | Chiesi Farma Spa | Kinase inhibitors |
| MY167216A (en) * | 2011-12-09 | 2018-08-14 | Chiesi Farm Spa | Kinase inhibitors |
| EP2875014B1 (en) * | 2012-07-17 | 2017-11-29 | Washington University | Anti-mucus drugs and uses therefor |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| EP2981535B8 (en) | 2013-04-02 | 2021-03-10 | Oxular Acquisitions Limited | Urea derivatives useful as kinase inhibitors |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP6514703B2 (ja) | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| ES2774249T3 (es) | 2014-02-14 | 2020-07-20 | Respivert Ltd | Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016145032A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| ES2935404T3 (es) * | 2015-10-01 | 2023-03-06 | Monsanto Technology Llc | Procedimiento de hidrogenación catalítica de halonitroaromáticos |
| AU2017245888B2 (en) | 2016-04-06 | 2021-05-13 | Oxular Acquisitions Limited | Kinase inhibitors |
| CA3142097A1 (en) * | 2018-05-30 | 2019-12-05 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
| MX2021003724A (es) | 2018-09-29 | 2021-05-14 | Jiangsu Yahong Meditech Co Ltd | Profarmaco de nitroxolina y su uso. |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN114144410A (zh) * | 2019-07-19 | 2022-03-04 | 阿纳格纳斯生物技术股份有限公司 | 多芳基脲衍生物及其在治疗肌肉疾病中的用途 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| AU2005273612B2 (en) | 2004-08-12 | 2010-10-14 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| DE102005015253A1 (de) * | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| JP2009518298A (ja) * | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| JP5236499B2 (ja) | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| JP2009525279A (ja) | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｐａｒモジュレーターとしてのスピロイミダゾール誘導体 |
| US20070194939A1 (en) | 2006-02-21 | 2007-08-23 | Alvarez Frank D | Healthcare facilities operation |
| BRPI0920707A2 (pt) * | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| MX2011006219A (es) | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
-
2010
- 2010-04-01 GB GBGB1005589.5A patent/GB201005589D0/en not_active Ceased
-
2011
- 2011-04-01 WO PCT/GB2011/050668 patent/WO2011121366A1/en not_active Ceased
- 2011-04-01 ES ES11713510.3T patent/ES2532764T3/es active Active
- 2011-04-01 JP JP2013501951A patent/JP5902668B2/ja active Active
- 2011-04-01 EP EP11713510.3A patent/EP2556065B1/en active Active
- 2011-04-01 US US13/638,640 patent/US20130029990A1/en not_active Abandoned
-
2016
- 2016-01-18 US US14/997,820 patent/US9771354B2/en active Active
-
2017
- 2017-08-29 US US15/689,075 patent/US10000471B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515836A5 (enExample) | ||
| ES2817902T3 (es) | N-acil-N'-(piridin-2-il) ureas y análogos que presentan actividades anticancerosas y antiproliferativas | |
| SI3008053T1 (en) | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS | |
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| JP2013523802A5 (enExample) | ||
| CA2903285C (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US8188113B2 (en) | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| JP2017527548A5 (enExample) | ||
| HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use | |
| SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
| JP2011507854A5 (enExample) | ||
| JP2013520473A5 (enExample) | ||
| HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
| RU2016115803A (ru) | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний | |
| TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| JP2014516074A5 (enExample) | ||
| JP2015529235A5 (enExample) | ||
| SI2925757T1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2014505735A5 (enExample) | ||
| JP2013528204A5 (enExample) | ||
| JP2013522354A5 (enExample) | ||
| JP2018524331A5 (enExample) | ||
| CA2749040A1 (en) | Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor |